Updated August 3, 2026

Wegovy Cost Without Insurance: What You'll Really Pay

Evan Brown
Written by Evan Brown
Prescription Savings Researcher
Dr Megan Harris Medically Reviewed by Dr. Megan Harris, MD
Editorial Review: This guide breaks down exactly what Wegovy costs without insurance in 2026 — list price, NovoCare Pharmacy self-pay tiers for both the pen and the oral pill, Medicare options, and every legitimate way to pay less — using publicly available Novo Nordisk pricing information current as of August 2026.
Quick Answer

Wegovy's list price is about $1,349/month, but almost no one actually pays that. Through NovoCare Pharmacy, Novo Nordisk's direct self-pay channel, uninsured patients can get the injection pen for about $349/month at any standard dose, or the oral pill starting around $149/month for the initial titration doses, rising to about $299/month at maintenance doses. Standard retail cash pricing without any manufacturer program runs $1,200–$1,400/month. Wegovy is not covered by Novo Nordisk's income-based Patient Assistance Program, and Medicare doesn't cover it for weight loss alone — though a separate $50/month Medicare GLP-1 Bridge option launched July 1, 2026 for eligible Part D beneficiaries, and Medicare Part D can cover Wegovy for its FDA-approved cardiovascular risk reduction use.

Key Takeaways

  • NovoCare Pharmacy self-pay is almost always cheaper than a standard retail cash price — confirm current tier pricing before filling anywhere else.
  • The oral Wegovy pill is generally the cheapest self-pay entry point, starting around $149/month.
  • Wegovy is not part of the income-based Novo Nordisk Patient Assistance Program as of 2026.
  • Medicare doesn't cover Wegovy for weight loss, but does cover it for cardiovascular risk reduction, and a separate $50/month Bridge program exists for some Part D beneficiaries.
  • Compounded semaglutide's legal availability narrowed significantly after the FDA resolved the national shortage in 2025 — confirm legitimacy before assuming it's a simple cheaper substitute.

The number that shows up first when you search "Wegovy price" — $1,349 a month — is real, but it's also close to the worst-case scenario. It's what you'd pay walking into a pharmacy with no insurance and no manufacturer program applied. Almost nobody actually pays that price, because Novo Nordisk sells Wegovy directly to cash-paying patients at a fraction of it.

This guide walks through what uninsured patients actually pay in 2026 — by format, by dose, and by program — plus the options that exist if you're on Medicare or looking for income-based help. If you're also comparing this against other GLP-1 costs, our drug price checker and manufacturer savings card guide can help you see the full landscape.

List Price vs What You Actually Pay

Understanding the gap between "list price" and "real price" is the single most useful thing to know before you start comparing pharmacies.

Price Type What It Means Approximate Amount
List price (WAC) The manufacturer's published price before any discount ~$1,349/month
Standard retail cash price What a typical pharmacy charges an uninsured walk-in with no program applied ~$1,200–$1,400/month
NovoCare Pharmacy self-pay Novo Nordisk's direct-to-patient cash price ~$149–$399/month, by format and dose

Why the gap is so large: List price reflects what would be billed before manufacturer rebates and discounts are applied through insurance. Since uninsured patients have no insurer negotiating on their behalf, Novo Nordisk created NovoCare Pharmacy specifically to offer a direct, negotiated cash price instead — which is why shopping through NovoCare almost always beats a standard retail cash price.

NovoCare Pharmacy Self-Pay Pricing by Format

Wegovy comes in two self-pay formats: the original injection pen and the oral tablet that launched in early 2026. Pricing differs meaningfully between them.

Format Dose Approximate Monthly Price
Injection pen 0.25 mg – 2.4 mg (standard doses) ~$349
Injection pen (high dose) 7.2 mg ~$399
Oral pill 1.5 mg / 4 mg (starter/titration) ~$149
Oral pill 9 mg / 25 mg (maintenance) ~$299

Tip: The oral pill is generally the cheapest legitimate brand-name entry point, but its price rises as your dose increases through titration. Ask your prescriber and confirm the current NovoCare price for your specific maintenance dose before assuming the starter price will hold long-term.

Full Cost Comparison Table

Here's how every realistic payment path compares side by side, from most to least expensive.

Path Approximate Monthly Cost Who It's For
Retail cash price, no program ~$1,200–$1,400 Anyone — but rarely the best option
NovoCare self-pay, injection pen ~$349 Uninsured patients preferring the pen
NovoCare self-pay, oral pill ~$149–$299 Uninsured patients wanting the lowest brand-name entry point
Commercial insurance + Wegovy Savings Card ~$0–$25 (if plan covers Wegovy) Insured patients with Wegovy coverage
Medicare GLP-1 Bridge (from July 1, 2026) ~$50 Eligible Medicare Part D beneficiaries

Prices shift often. NovoCare's self-pay tiers, the savings card's terms, and even retail cash pricing have all changed more than once during 2026. Treat these figures as a planning guide and confirm the current amount directly at novocare.com or wegovy.com before you commit to a specific pharmacy or program.

Eligibility Comparison

Program Insurance Required? Prescription Required?
NovoCare Pharmacy self-pay No Yes
Wegovy Savings Card Yes — commercial only Yes
Medicare GLP-1 Bridge Yes — Medicare Part D Yes
Standard Medicare Part D coverage Yes — for cardiovascular indication only Yes, with appropriate diagnosis

Income Limit Comparison

Unlike many patient assistance programs, none of Wegovy's main cost-reduction paths use income as a qualifying factor — which is an important, often-missed distinction.

Program Income Limit
NovoCare Pharmacy self-pay None
Wegovy Savings Card None
Novo Nordisk Patient Assistance Program Not applicable — Wegovy isn't covered by this program
Medicaid (in states that cover GLP-1s for obesity) Yes — varies by state

Important: Wegovy is not included in Novo Nordisk's free, income-based Patient Assistance Program as of 2026. That program currently covers select diabetes medications like Ozempic, but not weight-management drugs. If you need a truly free option based on financial need, Wegovy specifically isn't eligible for it — NovoCare self-pay is the lowest-cost manufacturer path available.

Covered Medications Comparison

Wegovy is FDA-approved for more than one use, and that distinction matters for insurance coverage.

Indication Medicare Coverage Commercial Insurance Coverage
Chronic weight management Not covered by Medicare Part D Varies widely by plan; often requires prior authorization
Cardiovascular risk reduction (in patients with known heart disease) Can be covered by Medicare Part D Generally covered, subject to plan rules

If your plan requires prior authorization before covering Wegovy for either indication, our prior authorization guide explains what that process typically involves.

How to Get NovoCare Self-Pay Pricing, Step by Step

1

Get a valid Wegovy prescription

This can come from your existing doctor or through a licensed telehealth provider if you don't have a prescriber already.

2

Create an account with NovoCare Pharmacy

Register at NovoCare's official website and select the self-pay option for Wegovy.

3

Choose pen or pill

Compare current pricing for both formats, since the pill is usually cheaper at starter doses but the price gap narrows or reverses at higher maintenance doses.

4

Confirm your dose-specific price before ordering

Pricing tiers are dose-dependent, especially for the pill. Confirm the exact current price for your specific prescribed dose before completing checkout.

5

Complete payment and shipping

No insurance information is required. Enter payment details and confirm your shipping address for home delivery.

Approval and Shipping Timelines

Step Typical Timeframe
NovoCare account setup Immediate to same-day
Prescription verification Same-day to a few business days
First shipment A few business days after order confirmation
Commercial insurance prior authorization (if applicable) Several days, plan-dependent

Renewal and Ongoing Pricing

  • NovoCare self-pay pricing is ongoing month to month as long as you keep reordering — there's no annual renewal requirement like an insurance-based savings card.
  • If your dose changes during titration, confirm the new price tier applies at your next order, since pill pricing especially depends on dose strength.
  • If you switch to commercial insurance that covers Wegovy, you can transition to the Wegovy Savings Card instead of continuing self-pay.
  • If you age into Medicare, NovoCare self-pay remains available to you, since it doesn't exclude Medicare beneficiaries the way the commercial savings card does.

Unlike commercial savings cards, which typically expire annually, NovoCare self-pay pricing doesn't have a similar renewal deadline — but the specific price tiers themselves can change during the year, so it's worth checking current pricing periodically rather than assuming last quarter's price still applies.


Common Mistakes That Cost You More

  • Filling at a standard retail pharmacy without checking NovoCare's self-pay price first, ending up paying three to four times more than necessary.
  • Assuming Wegovy qualifies for Novo Nordisk's free Patient Assistance Program — it currently doesn't.
  • Trying to use the Wegovy Savings Card without qualifying commercial insurance behind it.
  • Assuming the pill's starter price of $149 will hold at higher maintenance doses without checking the updated tier.
  • Assuming Medicare covers Wegovy for weight loss when it currently only covers the separate cardiovascular risk reduction indication, plus the newer Bridge program.
  • Purchasing compounded semaglutide from an unverified source without confirming its current legal standing and safety oversight.

The single most expensive mistake is simply not checking NovoCare pricing before filling elsewhere. The gap between a standard retail cash price and NovoCare's self-pay price can be $1,000 a month or more for the same medication.


Decision Tree: What Should You Do?

Step 1: Do you have commercial insurance that covers Wegovy?

✔ Yes → Use the Wegovy Savings Card for the lowest possible copay.

✖ No → Continue to Step 2.


Step 2: Are you on Medicare?

✔ Yes → Check whether you qualify for coverage under the cardiovascular risk reduction indication, or ask your Part D plan about the Medicare GLP-1 Bridge.

✖ No → Continue to Step 3.


Step 3: Are you uninsured?

✔ Yes → Use NovoCare Pharmacy self-pay pricing — start with the oral pill for the lowest entry cost, or the pen if you prefer that delivery method.


Practical Examples

Example 1 — Uninsured, new patient: An uninsured patient starts on the oral Wegovy pill through NovoCare at the $149/month starter tier, moving to the $299/month maintenance tier as their dose increases during titration.


Example 2 — Insured, plan covers Wegovy: A patient with employer insurance has their plan approve Wegovy after prior authorization. They activate the Wegovy Savings Card and pay close to $0–$25/month.


Example 3 — Medicare beneficiary: A Medicare Part D enrollee with documented cardiovascular disease gets Wegovy covered under the cardiovascular risk reduction indication, paying their plan's standard Part D cost-sharing rather than a self-pay price.


Pros and Cons of Each Path

NovoCare Pharmacy Self-Pay

  • No insurance or income verification required
  • Dramatically cheaper than standard retail cash pricing
  • Oral pill option offers the lowest brand-name entry price
  • Still hundreds of dollars a month, unlike the free Patient Assistance Program available for some other Lilly and Novo Nordisk medications
  • Pricing rises at higher maintenance doses for the pill

Wegovy Savings Card (Insured)

  • Lowest possible price of all the options, often under $25/month
  • No income verification needed
  • Requires commercial insurance that already covers Wegovy
  • Doesn't help if your plan denies coverage or you're uninsured

Bottom Line

If you're uninsured, the $1,349 list price shouldn't be your starting assumption — NovoCare Pharmacy's self-pay pricing brings the real cost down to a fraction of that, especially with the oral pill. If you have commercial insurance that covers Wegovy, the savings card gets you even lower. Medicare beneficiaries have narrower options, but the cardiovascular indication and the new GLP-1 Bridge program are both worth checking before assuming Wegovy is out of reach.

Whichever path applies to you, confirm the current price directly before committing — this is one of the fastest-moving pricing categories in prescription drugs right now.

Want to see your actual price before you commit?

Compare NovoCare self-pay pricing, your insurance copay, and other savings options side by side.

Compare Prices Now → See All Manufacturer Savings Cards

Frequently Asked Questions

Wegovy's list price is about $1,349 per month, but almost no uninsured patient pays that. Through Novo Nordisk's NovoCare Pharmacy self-pay program, the injection pen runs about $349/month at any dose, and the oral pill starts around $149/month for starter doses, rising to about $299/month at maintenance doses. Retail cash prices at a standard pharmacy without any manufacturer program typically run $1,200 to $1,400/month.

Yes, generally. Through NovoCare Pharmacy self-pay, the oral Wegovy pill starts around $149/month at the starting dose, compared to about $349/month for the injection pen at any dose. The pill's price does rise at higher maintenance doses, so confirm the current tier for your specific dose before assuming it stays at the starter price.

Medicare Part D does not cover Wegovy for weight loss alone, but it can cover Wegovy when prescribed for its FDA-approved cardiovascular risk reduction indication in patients with known heart disease. Separately, starting July 1, 2026, eligible Medicare Part D beneficiaries can access Wegovy for about $50/month through the Medicare GLP-1 Bridge program, subject to plan participation.

No. As of 2026, Wegovy is not included in Novo Nordisk's income-based Patient Assistance Program, which covers select diabetes medications like Ozempic but not weight-management drugs. Uninsured patients seeking a lower price should look at NovoCare Pharmacy self-pay pricing instead, since it's not income-based.

No. The Wegovy Savings Card is a copay assistance card for people with commercial insurance that covers Wegovy — it reduces an existing copay rather than replacing insurance. If you're uninsured, NovoCare Pharmacy's self-pay pricing is the manufacturer program built for your situation instead.

Compounded semaglutide is sometimes advertised at a lower monthly price, but its legal availability narrowed significantly after the FDA resolved the national semaglutide shortage in 2025, since compounding is only broadly permitted during an active drug shortage or for individual patients with a specific documented medical need. Talk to your prescriber about whether a compounded product is appropriate and legally available to you before assuming it's a straightforward cost-saving option.

For the injection pen, NovoCare Pharmacy self-pay pricing is generally the same across all standard doses from 0.25 mg through 2.4 mg, with the high-dose 7.2 mg pen priced separately and higher. For the oral pill, pricing is tiered, starting lower for the initial titration doses and increasing at higher maintenance doses.

Usually not. Discount coupon services like GoodRx generally apply to the higher retail cash price, which typically still lands well above NovoCare's direct self-pay pricing. Compare both before filling, but expect NovoCare to come out ahead in most cases for uninsured patients.

It depends on your state. A limited number of state Medicaid programs cover GLP-1 medications like Wegovy for obesity treatment, while most do not. Check with your state Medicaid program directly to confirm current coverage rules where you live.

If your commercial plan denies coverage, the Wegovy Savings Card's standard tier won't apply since it requires existing coverage to reduce. In that case, compare NovoCare Pharmacy self-pay pricing while your prescriber pursues an appeal or prior authorization request on your behalf.


How We Researched This Guide

This guide was prepared by the Refill Relay Editorial Team using publicly available Novo Nordisk NovoCare Pharmacy pricing information, Wegovy Savings Card terms, current 2026 Medicare Part D and GLP-1 Bridge program guidance, and standard retail cash pricing data.

Every article undergoes editorial review for accuracy, readability, and consistency before publication. Our goal is to explain prescription pricing in clear language so patients can find the option that actually applies to their situation.


References

  1. Novo Nordisk. NovoCare Pharmacy Self-Pay Pricing and Wegovy Savings Card Terms.
  2. Novo Nordisk. Wegovy Official Pricing and Prescribing Information.
  3. U.S. Food & Drug Administration. Semaglutide Products, Approved Indications, and Compounding Guidance.
  4. Medicare.gov. Prescription Drug Coverage and GLP-1 Access Guidance.
  5. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Guidance.

About Refill Relay

Refill Relay publishes evidence-based educational resources that help patients understand prescription insurance, patient assistance programs, pharmacy benefits and medication access. Our editorial team combines manufacturer program research with practical guidance to make complex healthcare topics easier to navigate.

Editorial Standards

  • Evidence-based program research
  • Editorial review before publication
  • Regular updates when pricing or program rules change
  • Clear distinction between educational content and medical or financial advice

Related Resources

Editorial Policy: Refill Relay content is researched using publicly available manufacturer materials, federal guidance, and standard industry pricing practices. Every article is reviewed for clarity, accuracy and usefulness before publication. Pricing and program terms change periodically — confirm current amounts at Novo Nordisk's official NovoCare and Wegovy sites before enrolling. This content is educational and is not medical advice.

Evan Brown
About the Author
Evan Brown — Prescription Savings Researcher

Evan Brown is a prescription savings researcher who specializes in translating complex manufacturer pricing programs into clear, actionable guidance for patients.

View Full Profile →
Dr. Megan Harris, MD
Medical Review
Dr. Megan Harris, MD — Board-Certified Internal Medicine

Dr. Megan Harris, MD reviews health content for accuracy, checking pricing claims and coverage details against current manufacturer and CMS guidance.

View Full Profile →

Contact Refill Relay